Compare MCK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCK | VRTX |
|---|---|---|
| Founded | 1833 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.8B | 135.6B |
| IPO Year | 1995 | 2006 |
| Metric | MCK | VRTX |
|---|---|---|
| Price | $1,091.18 | $534.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 32 |
| Target Price | ★ $1,144.29 | $595.36 |
| AVG Volume (30 Days) | 633.6K | ★ 1.4M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | 49.22 | ★ 836.54 |
| EPS | ★ 15.53 | 10.90 |
| Revenue | ★ $112,084,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $7.94 | $10.46 |
| Revenue Next Year | $6.87 | $10.53 |
| P/E Ratio | $71.16 | ★ $49.34 |
| Revenue Growth | 3.11 | ★ 46.20 |
| 52 Week Low | $723.68 | $412.27 |
| 52 Week High | $1,121.50 | $568.67 |
| Indicator | MCK | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 49.75 |
| Support Level | $835.39 | $493.75 |
| Resistance Level | $1,121.50 | $536.58 |
| Average True Range (ATR) | 25.91 | 16.14 |
| MACD | 3.20 | -1.47 |
| Stochastic Oscillator | 78.91 | 14.27 |
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).